Bristol-Myers Squibb Company stock price, BMY

Bristol-Myers Squibb Company stock chart:



Bristol-Myers Squibb Company close price: 53.48

Stock price forecast:

DOWN TO -3.53%
Target: 51.59

Total forecasts: 82
Reached: 48 (58.54%)

Total Win: 68.68 (129.83%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
90834959.04%69.551.59%1,847.74-38.70-2.09%30.850.69%
302300.00%0.000.00%1,232.65-3.25-0.26%-3.25-0.26%
141500.00%0.000.00%796.964.600.58%4.600.58%
7800.00%0.000.00%425.142.060.48%2.060.48%

Showing 1-10 of 406 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-04-2353.4851.510000-00-00
2017-04-2253.4851.480000-00-00
2017-04-2153.4451.060000-00-00
2017-04-2053.250.310000-00-00
2017-04-1952.9354.250000-00-00
2017-04-1852.9554.620000-00-00
2017-04-1752.8354.730000-00-00
2017-04-1652.8354.760000-00-00
2017-04-1552.8354.80000-00-00
2017-04-1452.8354.830000-00-00

Bristol-Myers Squibb Company latest news:


  • 04/21/2017 12:19:56

    BRIEF-Bristol-Myers gets positive CHMP opinion recommending approval of Opdivo for treatment of a type of bladder cancer

    * Bristol-Myers Squibb receives positive CHMP opinion recommending approval of Opdivo (Nivolumab) for the treatment of patients with previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer

  • 04/03/2017 09:07:05

    Bristol-Myers Squibb says cancer drug combination 'significantly' improved survival in late-stage melanoma trial

    Bristol-Myers Sqibb Co. said Monday morning that the combination of its two cancer drugs showed the best survival rates in melanoma patients in a late-stage clinical trial. The combination of the drugs Opdivo and Yervoy is one many Wall Street analysts believe is promising. Two-year overall survival rates for patients with previously untreated advanced melanoma were highest for the combination treatment, or 64%, followed by 59% for Opdivo alone and 45% for Yervoy alone, according to the company. The phase 3 trial enrolled 945 patients, and had a minimum follow-up period of 28 months. Bristol-Myers said that the clinical trial was not designed to compare Opdivo in combination with Yervoy with Opdivo alone, but that analyses found a relative reduction in death risk of 12% for the combination treatment, with risk of death reduced especially for patients with the PD-L1 biomarker of less than 1%. That's an important distinction, said EvercoreISI analyst Umer Raffat, who said the findings could have implications for an ongoing lung cancer trial. "Could the [Opdivo and Yervoy] combo have a better shot in the

  • 02/21/2017 15:24:08

    Icahn buys Bristol-Myers shares, adding to activist pressure

    - Billionaire investor Carl Icahn has taken a stake in Bristol-Myers Squibb Co (BMY) and sees the drugmaker as a possible takeover target, according to a report published on Tuesday that sent the company's shares from a loss to more than 2 percent higher.

  • 02/02/2017 16:33:37

    BRIEF-Bristol-Myers Squibb receives FDA approval for Opdivo (Nivolumab)

    * Bristol-Myers Squibb receives FDA approval for Opdivo (Nivolumab) in previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer

  • 01/26/2017 05:19:21

    Bristol-Myers Squibb stock sinks 2.7% after fourth-quarter earnings miss and downbeat outlook

    Bristol-Myers Sqibb shares sunk 2.7% in pre-market trade Thursday after the company reported a fourth-quarter earnings miss and revenue beat. Earnings for the latest quarter were $894 million, or 53 cents per share. In the year-earlier period the company had a loss of $197 million, or 12 cents per share. Adjusted EPS was 63 cents, compared with the FactSet consensus of 67 cents. Revenue rose to $5.24 billion from $4.29 billion, beating the FactSet consensus of $5.12 billion. The company said global revenue growth was driven by sales for its blockbuster cancer drug Opdivo, along with drugs Eliquis, Orencia, Sprycel and Yervoy. Bristol-Myers confirmed its 2017 EPS guidance range of $2.47 to $2.67 and reduced its adjusted EPS guidance range to $2.70 to $2.90 from $2.85 to $3.05. Shares of Bristol-Myers have risen 0.5% over the last three months, compared with a 7.4% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Bristow Group IncBRS | Brixmor Property Group Inc.BRX | Broadridge Financial SolutionsBR | Brookdale Senior Living Inc.BKD | Brookfield Asset Management IncBAM | Brookfield Canada Office PropertiesBOXC | Brookfield DTLA Inc.DTLA^ | Brookfield Global Listed Infrastructure Income FunINF | Brookfield High Income Fund Inc.HHY | Brookfield Infrastructure Partners LPBIP |